Excess Copper Chelating Therapy for Wilson Disease Induces Anemia and Liver Dysfunction

被引：11

作者：

Harada, Masaru ^{[1
]}

Miyagawa, Koichiro ^{[1
]}

Honma, Yuichi ^{[1
]}

Hiura, Masaaki ^{[1
]}

Shibata, Michihiko ^{[1
]}

Matsuhashi, Toru ^{[1
]}

Abe, Shintaro ^{[1
]}

Harada, Riko ^{[1
]}

Tabaru, Akinari ^{[1
]}

机构：

[1] Univ Occupat & Environm Hlth, Japan Sch Med, Dept Internal Med 3, Tokyo, Japan

来源：

INTERNAL MEDICINE | 2011年 / 50卷 / 14期

关键词：

ceruloplasmin; chelating therapy; hemochromatosis; Wilson disease; ACQUIRED SIDEROBLASTIC ANEMIA; LATE ENDOSOMES; IRON; GENE; CERULOPLASMIN; ATP7B; ACERULOPLASMINEMIA; FERROPORTIN; DIAGNOSIS; HEPCIDIN;

D O I：

10.2169/internalmedicine.50.5209

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 37-year-old man was diagnosed with Wilson disease at the age of 14. His first manifestations were neurological. He was treated with trientine for more than 10 years and suffered from anemia and liver dysfunction. Wilson disease is a genetic disorder characterized by accumulation of copper in the body. Excess copper is toxic, but copper is an essential trace element. Copper-binding ceruloplasmin is important for iron metabolism. Excess copper chelating treatment-induced anemia and iron deposition in the liver was suspected. Proper monitoring of copper status is important for the management of Wilson disease.

引用

页码：1461 / 1464

页数：4

共 45 条

[41] Investigating the influence of standard staining procedures on the copper distribution and concentration in Wilson's disease liver samples by laser ablation-inductively coupled plasma-mass spectrometry
Hachmoeller, Oliver
Aichler, Michaela
Schwamborn, Kristina
Lutz, Lisa
Werner, Martin
Sperling, Michael
Walch, Axel
Karst, Uwe
[J]. JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, 2017, 44 : 71 - 75
[42] The Effects of Testosterone Replacement Therapy in Adult Men With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-analysis
Mahmoud, Maya
Kawtharany, Hassan
Awali, Mohamed
Mahmoud, Nadine
Mohamed, Islam
Syn, Wing-Kin
[J]. CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2025, 16 (01)
[43] Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy
Xia, Mengying
Varmazyad, Mahboubeh
Pla-Palacin, Iris
Gavlock, Dillon C.
De Biasio, Richard
La Rocca, Gregory
Reese, Celeste
Florentino, Rodrigo M.
Faccioli, Lanuza A. P.
Brown, Jacquelyn A.
Vernetti, Lawrence A.
Schurdak, Mark
Stern, Andrew M.
Gough, Albert
Behari, Jaideep
Soto-Gutierrez, Alejandro
Taylor, D. Lansing
Miedel, Mark T.
[J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
[44] Copper induces liver lipotoxicity disease by up-regulating Nrf2 expression via the activation of MTF-1 and inhibition of SP1/Fyn pathway
Zhong, Chong-Chao
Zhao, Tao
Hogstrand, Christer
Song, Chang-Chun
Zito, Ester
Tan, Xiao-Ying
Xu, Yi-Chuang
Song, Yu-Feng
Wei, Xiao-Lei
Luo, Zhi
[J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2023, 1869 (06):
[45] Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes-Interventional Study
Hachula, Marcin
Kosowski, Michal
Basiak, Marcin
Okopien, Boguslaw
[J]. PHARMACEUTICALS, 2023, 16 (09)

← 1 2 3 4 5 →